1. Introduction {#sec1}
===============

Peptides, owing to their feasible rational design, high specificity, and low toxicity, have become attractive therapeutic agents to treat different diseases \[[@B1]\]. Ongoing advances in cancer therapy include the discovery of peptides with a potent antineoplastic effect \[[@B2]\]. Peptides inhibiting angiogenesis or blocking protein-protein interactions have already been evaluated as potential anticancer agents \[[@B3]\]. Additionally, proapoptotic peptides or peptides functioning as receptor antagonists have been proposed to restrict tumor progression \[[@B3]\].

CIGB-552 is a second-generation peptide derived from the antitumor peptide L-2. Initially, L-2 was identified by screening a peptide library corresponding to the region 32--51 of*Limulus* anti-LPS factor (LALF) \[[@B4]\]. The cytotoxic effect of L-2 was demonstrated on different murine and human tumor cell lines \[[@B4]\]. A transcriptomic study on tumor cells suggested that L-2 could induce apoptosis by modulating glycolysis, mitosis, protein biosynthesis, and other cancer related processes \[[@B4]\].

Such biological findings, in combination with the peptide cell-penetrating capacity, made L-2 an attractive lead molecule for further structural optimization. Therefore, the primary sequence of L-2 was modified, including substitution by D-amino acids and N-terminal acetylation \[[@B5]\]. These modifications increased the antitumor effect of the resultant peptide known as CIGB-552 \[[@B5], [@B6]\].

The CIGB-552*in vitro* antineoplastic effect has been documented by using human cancer cells of different histological origins \[[@B5]\].*In vivo*, a significant reduction in tumor growth after treatment with CIGB-552 was demonstrated in both syngenic murine tumors and patient-derived xenograft models \[[@B6]\]. Additionally to induce apoptosis in the tumor mass, CIGB-552 administration decreased the microvessels\' density in the human HT-29 xenograft tumor model suggesting its antiangiogenic effect \[[@B6]\].

Significant advances have been made to discover the functional mediators of CIGB-552 biological response. Copper metabolism (Murr1) domain-containing protein 1 (COMMD1) has been identified as a major target of CIGB-552. Such interaction increased the COMMD1 stability and induced ubiquitination of RelA with subsequent inhibition of the antiapoptotic activity regulated by NF-*κ*B \[[@B5]\]. Nevertheless, the proteome regulated by CIGB-552 can provide new insights to support the antitumor action mechanism of such peptide.

In this work, to identify additional CIGB-552 targets and modulated proteins in tumor cells, two proteomics approaches were used: the chemical proteomics and the expression-based proteomics. The proteomics-derived data suggested that CIGB-552 could be considered as a multitarget drug, which exerts its antitumor effect by modulating proteins related to NF-*κ*B activation, cell cycle regulation, and apoptosis. Network analysis of proteomic results indicates the molecular basis by which the CIGB-552 peptide regulates cancer related processes. The analysis provided here is the starting point for further investigations about the role of CIGB-552 as an anticancer drug.

2. Materials and Methods {#sec2}
========================

2.1. Peptide Synthesis {#sec2.1}
----------------------

CIGB-552 is a cell-penetrating peptide with sequence Ac-HARIK**P**TFRR**L**KWKYKGKFW, where proline and leucine are D-amino acids; and the N-terminal was blocked by acetylation \[[@B5]\]. The CIGB-552 peptide was synthesized on solid phase using the Fmoc strategy; it was purified by reverse phase high performance liquid chromatography (RP-HPLC) to \>95% purity on an acetonitrile/H~2~O-trifluoroacetic acid gradient \[[@B7]\] and confirmed by electrospray mass spectrometry (Micromass, UK). For chemical proteomics, the CIGB-552 peptide biotinylated at the N-terminal end (CIGB-552-B) was synthesized using the same procedure.

2.2. Cell Culture and Treatments {#sec2.2}
--------------------------------

For proteomic studies two CIGB-552 sensitive cancer cell lines were selected, the larynx carcinoma and colon adenocarcinoma cells, Hep-2 and HT-29, respectively, which were obtained from ATCC (Rockville, MD). Both cell lines were cultured at 37°C and 5% CO~2~ in RPMI 1640 (Life Technologies, USA) supplemented with 10% fetal bovine serum (FBS; PAA, Canada) and 30 *μ*g/mL gentamicin (Sigma, USA).

For expression-based proteomics, 20 × 10^6^ HT-29 cells were seeded in appropriate vessels and incubated for 24 h. Subsequently, the tumor cells were incubated with 150 *μ*mol/L of CIGB-552 during 40 min, 2 h, and 5 h.

2.3. Chemical Proteomics {#sec2.3}
------------------------

### 2.3.1. Isolation of Proteins {#sec2.3.1}

For chemical proteomics, 20 × 10^6^ Hep-2 cells were seeded in appropriate vessels and cultured for 24 h. Subsequently, Hep-2 cells were collected by centrifugation, washed twice with cold phosphate buffered saline (PBS), and lysed in hypotonic PBS solution (0.1x), containing 1 mM of DDT (Sigma) and complete protease inhibitor (Roche, USA), by three freeze-thaw (37°C) cycles. Cellular lysate was cleared by centrifugation at 12 000 rpm at 4°C for 15 min.

### 2.3.2. Affinity Purification {#sec2.3.2}

The CIGB-552-B peptide was incubated with 50 *μ*L of streptavidin-sepharose matrix (binding capacity: 300 nmol/mL; GE Healthcare, USA) for 1 h. As a control, streptavidin-sepharose matrix without CIGB-552-B peptide was used. Then, 300 *μ*g of total protein from Hep-2 cell lysate, as determined by the Bradford assay (Bio-Rad, USA), was added to each matrix and incubated for 2 h at 4°C. The streptavidin-sepharose matrix was collected by short spin and extensively washed with PBS containing 1 mM DTT and 0.5% NP40. Retained proteins were eluted by heat denaturing with SDS sample buffer.

### 2.3.3. Sample Preparation and LC-MS/MS Analysis {#sec2.3.3}

Affinity-purified proteins were reduced, alkylated with acrylamide, and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Analytical and preparative gels were silver \[[@B8]\] and Coomassie blue stained, respectively. Each lane of the preparative gel was cut into 12 slices that were faded, washed, and*in situ* digested with sequencing grade trypsin (Promega, USA) during 18 h at 37°C. The resulting peptide mixtures were extracted and desalted with stage tips (Thermo Scientific, USA).

Purified samples were analyzed in an Agilent 1100 series nano LC system (Agilent, USA) coupled online to a QTof-2 tandem mass spectrometer (Micromass, UK). The capillary and cone voltages of the electrospray ionization source were operated with 1.8 kV and 35 V, respectively. Samples were applied at 20 *μ*L/min to a PepMap C18 Precolumn Cartridge (5 mm × 300 *μ*m i.d.) from LC-Packings (USA) and were extensively desalted for 10 min using 0.1% formic acid. The precolumn was switched back onto a C18 capillary column (15 cm × 75 *μ*m i.d., packed with 5 *μ*m, Zorbax 300 SB) and the tryptic peptides were separated using a mobile phase containing 0.1% formic acid, 5--45% acetonitrile gradient over 90 min at 300 nL/min flow rate. Survey scans were acquired during 1 s and a maximum of 4 concurrent MS/MS acquisitions were only triggered for 2+, 3+ charged precursors ions detected at an intensity above a threshold of 15 counts/s. Each MS/MS acquisition was completed and switched back to MS mode when the total ion current fell below a threshold of 2 counts/s or after a maximum of 6 s of continuous acquisition. Data acquisition and processing were performed using MassLynx v3.5 (Micromass, UK).

### 2.3.4. Protein Identification {#sec2.3.4}

Acquired data were searched against the human proteins in the UniProtKB database using MASCOT (version 2.2, Matrix Science, UK) \[[@B9]\]. Search parameters were set to a mass tolerance of 1.2 Da for the precursor ions and 0.6 Da for the fragment ions. One trypsin missed cleavage site was allowed. Propionamide-cysteine and oxidized methionine were set as fixed and variable modifications, respectively. MS/MS spectra of identified proteins with one or two peptides were manually inspected. The identification of a protein or peptide was considered positive using the consensus of several criteria: the peptide score \>20, the assignment of four intense consecutive *y* ~*n*~′′ fragments ions in the MS/MS spectrum, and the most intense signals which must be explained considering the proposed sequence.

### 2.3.5. Bioinformatics Analysis {#sec2.3.5}

Functional classification of identified proteins was based on the information annotated in the Gene Ontology (GO) database (<http://www.geneontology.org>). The analysis was performed using the functional enrichment tool GeneCodis (version 3.0) (<http://genecodis.cnb.csic.es/>) \[[@B10]\]. To identify significant enriched biological processes (*p* values lower than 0.05), the hypergeometric distribution and the false discovery rate (FDR) correction method were computed by GeneCodis, as statistical analysis. Protein complexes associated with the CIGB-552 target profile were identified by using the CORUM database (<http://mips.helmholtz-muenchen.de/genre/proj/corum>) \[[@B11]\].

A target deconvolution strategy was applied to filter the CIGB-552 target profile. Nonspecific proteins, retained in unloaded streptavidin-sepharose matrix (without CIGB-552-B), were ruled out. Further, proteins reported by Burkard et al. \[[@B12]\] as part of the central proteome were subtracted from the analysis. To identify contaminants or background proteins the potential CIGB-552 target profile was queried against the CRAPome database (<http://www.crapome.org>). For each protein, the average spectral count was retrieved as a measure of its abundance in affinity purification followed by mass spectrometry (AP-MS) experiments \[[@B13]\].

Functional subnetworks perturbed by CIGB-552 were identified by using drugDisruptNet (<http://bioinformatics.cemm.oeaw.ac.at/index.php/downloads-left/87-disruption-of-functional-networks>). The impact of CIGB-552 on functional subnetworks was estimated by the score *S* ~net~, which was calculated as described by Burkard et al. \[[@B14]\] but with some modifications. In this regard, the affinity of CIGB-552 to its targets (affinity score) was computed irrespective of the protein abundance in a competitive pull-down (fixed to 1 for all potential CIGB-552 targets). Hence, the affinity score was set to be only proportional to the amount of protein pulled down by CIGB-552-B. As a measure of protein abundance, the exponentially modified Protein Abundance Index (emPAI) of each identified protein was retrieved from MASCOT results. Briefly, the emPAI value is calculated as 10^PAI^ − 1 (PAI = observed peptides/observable peptides), being the number of different observed peptides that cover the protein sequence, a rough estimate of the protein amount in mass spectrometric analysis \[[@B15]\].

2.4. Expression-Based Proteomics {#sec2.4}
--------------------------------

### 2.4.1. Isolation of Cytosolic Proteins {#sec2.4.1}

HT-29 cells were collected by trypsinization. After washing with PBS, the cells were suspended in 700 *μ*L of the isotonic buffer containing 10 mM Tris-HCl adjusted to pH 7.5, 0.25 M sucrose, 1 mM EGTA, and protease inhibitors. For plasma membrane solubilization Triton X-100 at final concentration of 0.25% was added. After 15 min at 4°C, the cell lysate was centrifuged for 15 min at 12 000 rpm and 4°C. The supernatant containing cytoplasmic proteins was kept at −70°C until subsequent analysis.

### 2.4.2. Tryptic Digestion and Isobaric Labeling (iTRAQ) {#sec2.4.2}

The cytoplasmic protein extracts (120 *μ*g) of CIGB-552-treated and untreated (control) HT-29 cells were precipitated with acetone/TCA and independently dissolved in 20 *μ*L of buffer containing 2 M guanidinium hydrochloride (GuCl) and 500 mM tetraethylammonium bromide (TEAB), pH 8.5. Proteins were reduced using 49 mM tris-2-carboxyethyl phosphine (TCEP) at 60°C for 1 h and alkylated with 84 mM iodoacetamide for 30 min at ambient temperature in the dark. The pool of reduced and S-alkylated proteins was diluted until 50 *μ*L by adding 500 mM TEAB buffer. Proteins were digested with sequencing grade trypsin (Promega, USA) at an enzyme-to-substrate mass ratio of 1 : 10 for 18 h at 37°C.

Tryptic peptides were labeled with iTRAQ reagent according to the manufacturer\'s protocol (Applied Biosystems, USA). Briefly, each vial of iTRAQ reagent (114--117 tags) was dissolved in 70 *μ*L ethanol by vortexing for 1 min at room temperature. Equal amounts of tryptic peptides derived from different samples were labeled by adding iTRAQ reagent 114 (untreated HT-29 cells, control), iTRAQ reagent 115 (HT-29 cells treated with CIGB-552 for 40 min), iTRAQ reagent 116 (HT-29 cells treated with CIGB-552 for 2 h), and iTRAQ reagent 117 (HT-29 cells treated with CIGB-552 for 5 h). The reaction for iTRAQ labeling was incubated at room temperature for 1 h. Labeled peptides were mixed and dried in a centrifugal evaporator.

### 2.4.3. LC-MS/MS Analysis {#sec2.4.3}

A high pH reversed-phase chromatography step was used to separate the complex mixture of peptides prior to LC-MS/MS analysis. The labeled peptides were resuspended in 500 *μ*L buffer A (0.1% NH~4~OH, pH 10.5) and separated in 24 fractions using a 4.6 mm × 10 cm RP column packed with POROS R2 resin (Applied Biosystems, USA). Peptides were eluted at a flow rate of 0.8 mL/min using a stepwise buffer B (0.1% NH~4~OH, 60% acetonitrile, pH 10.5) gradient. Collected fractions were acidified by adding 200 *μ*L of 5% formic acid, lyophilized, and further dissolved in 200 *μ*L of 0.2% formic acid.

For each fraction, three replicate aliquots of 40 *μ*L were separated in independent LC-MS/MS experiments by reverse phase chromatography. Peptides were separated and analyzed using an Agilent 1100 series nano-LC system (Agilent, USA) coupled online to a QTof-2 orthogonal hybrid tandem mass spectrometer (Micromass, UK) operated as described above. Peptides were eluted at a flow rate of 300 nL/min using a 60 min gradient starting with 5% acetonitrile to 45% acetonitrile with a two-buffer system (Buffer A: 0.2% formic acid; Buffer B: 0.2% formic acid, 80% acetonitrile). Data dependent acquisition MS/MS spectra of the eluted peptides were acquired in three*m/z* ranges (400--600, 590--900, or 890--2000) using the gas-phase fractionation approach \[[@B16]\]. Subsequent analysis proceeded as described above.

### 2.4.4. Protein Identification {#sec2.4.4}

Raw files were processed using MASCOT Distiller software (version 2.3). Peptides were assigned to MS/MS spectra using MASCOT search engine (version 2.2) against the human proteins in the UniProtKB database. The following search parameters were selected: 1.2 Da precursor mass tolerance, 0.6 Da daughter ions mass tolerance, and tryptic search with up to one missed cleavage site. Variable modifications including deamidation of glutamine and asparagine, methionine sulfoxide, and the side reaction of iTRAQ labeling on tyrosine residues were taken into account. Carbamidomethyl cysteine and iTRAQ label on lysine and at the peptide N-terminus were specified as fixed modifications. To accept a peptide hit as positive we considered a false discovery rate (FDR) of 3% based on the target-decoy strategy \[[@B17]\].

Quantification was achieved using ISOTOPICA software \[[@B18], [@B19]\]. The software enables the relative peptide quantification based on the detailed analysis of the observed isotopic ion distribution. The software calculated the best ratio of the reporter ions (tags 114, 115, 116, and 117) to obtain an*in silico* isotopic ion distribution best matching with the isotopic ion distribution observed experimentally. To evaluate the quality of this adjustment, the software calculates the difference between the area of both*in silico* and experimental isotopic ion distributions, and it is expressed as a GOF coefficient (goodness of fitting). The relative quantifications of peptides with GOF below 0.8 were not considered for further analysis. Additionally all relative quantifications were manually inspected. The relative peptide expression ratios (fold changes) were determined with respect to the control sample (tag 114). The fold changes of all peptides corresponding to the same protein were averaged. The resulting protein fold changes were normalized; population median and standard deviation set the threshold ratio to consider, with a *p* value \< 0.1, a protein as differentially expressed in each condition (HT-29 cells treated with CIGB-552 for 40 min, 2 h, or 5 h) with respect to control (untreated HT-29 cells).

### 2.4.5. Bioinformatics Analysis {#sec2.4.5}

The functional classification of differentially expressed proteins and enrichment analysis were performed as described above. For biological network analysis, the Cytoscape software (version 2.8) \[[@B20]\] and accessory applications were used. Protein-protein interaction network was generated using the BisoGenet application (version 1.4) \[[@B21]\] which retrieves information from interaction databases including DIP, BioGrid, HPRD, and BIND. The fold changes of differentially expressed proteins were visualized in the network context using the MultiColoredNodes application \[[@B22]\].

3. Results and Discussion {#sec3}
=========================

CIGB-552 is a peptide-based drug with antitumor effect and cell-penetrating capacity \[[@B4]\]. The first evidence about CIGB-552 mechanism of action has been already reported \[[@B5]\]. CIGB-552 interacts with COMMD1 protein, increasing its abundance levels. Such evidences were corroborated by Western blot and immunofluorescence detection of COMMD1 in human cancer cells of different histological origins \[[@B5]\]. CIGB-552 induces cellular cytotoxicity in a variety of tumor cell lines \[[@B4], [@B5]\]. Among them, the Hep-2 larynx carcinoma cell line is highly sensitive to CIGB-552 cytotoxic effect.

To identify other proteins that interact with CIGB-552 a chemical proteomic approach was then conducted ([Figure 1(a)](#fig1){ref-type="fig"}). PBS-soluble proteins derived from Hep-2 cells were incubated with CIGB-552-B previously bound to the streptavidin-sepharose matrix ([Figure 1(a)](#fig1){ref-type="fig"}). As a negative control, the same pool of proteins was also incubated with the unloaded streptavidin-sepharose matrix. CIGB-552 interacting proteins were eluted and analyzed by SDS-PAGE ([Figure 1(b)](#fig1){ref-type="fig"}). The electrophoretic pattern of the whole cell extract and CIGB-552-matrix eluted proteins showed appreciable differences in terms of band intensities indicating the potential CIGB-552 target profile. The proteins identified in the negative control correspond to proteins that interact with the matrix, known as either nonspecific binders or sticky proteins.

A total of 265 proteins were identified by mass spectrometry, of which 104 proteins were also identified as nonspecific binders (see Supplementary Table S1a in the Supplementary Material available online at <http://dx.doi.org/10.1155/2015/124082>). Therefore, 161 proteins constitute the potential CIGB-552 target profile identified by chemical proteomics. Biological processes related to carbohydrate metabolism, protein modification, and cell cycle are significantly represented on this dataset ([Figure 2](#fig2){ref-type="fig"}). Interestingly, such biological processes are also represented in the transcriptomic profile regulated by L-2 peptide in Hep-2 tumor cells \[[@B4]\].

The potential CIGB-552 target profile identified*in vitro* includes five biological complexes ([Figure 3](#fig3){ref-type="fig"}). Components of the minichromosome maintenance (MCM) complex were identified as potential CIGB-552 targets. The MCM complex is related to DNA replication and cell cycle regulation. Therefore, the MCM proteins are frequently upregulated in different cancer types including meningioma, lung cancer, and laryngeal carcinoma \[[@B23]--[@B26]\]. Four components of the 60S ribosomal large subunit were also identified. Accordingly, translation is a biological process overrepresented in the CIGB-552 target profile ([Figure 2](#fig2){ref-type="fig"}). Related to protein modification process, five components of the ubiquitin E3 ligase complex were found. In addition, nine subunits of the proteasome complex were included in the CIGB-552 target profile.

Chemical proteomics do not distinguish between drugs direct and indirect binders. In addition, a high background is typically identified in these experiments \[[@B27]\]. Therefore, the 161 proteins found in the chemical proteomic profile might include nonspecific binders of CIGB-552. Potential solutions to overcome the specificity problem of chemical proteomics are (i) to include unrelated drugs or the matrix itself as negative controls, (ii) to identify and subtract from the analysis the abundant proteins or core proteome, and (iii) to perform a competitive pull-down to rank the most relevant targets \[[@B28]\].

In the present study, besides identifying nonspecific binders, the core proteome was subtracted from the potential CIGB-552 target profile. A set of 1124 proteins previously identified as part of the human central proteome was used \[[@B12]\]. The potential CIGB-552 target profile (161 proteins) includes 106 proteins of the central proteome. The majority of these proteins (91/106) were also reported with an average spectral count greater than two in the CRAPome database (Supplementary Table S1a-b). The spectral count is used as a measure of protein abundance in affinity purification (AP) experiments \[[@B13]\]. Therefore, the CRAPome repository gives information about abundant proteins or common contaminants of AP-MS experiments.

By subtracting the central proteome, 55 proteins were identified as the most probable targets of CIGB-552 ([Table 1](#tab1){ref-type="table"}). This result suggests the potentialities of CIGB-552 as a multitarget drug. In contrast to previously published results \[[@B5]\], the COMMD1 protein was not identified in the chemical proteomic profile, probably due to its low expression levels in tumor cells \[[@B29]\].

The central proteome is mainly enriched in cell vital processes \[[@B12]\]. Consequently, after the central proteome subtraction, biological processes such as translation, transport, response to stress, and cell death are no longer significantly represented in the CIGB-552 chemical proteomic profile. However, proteins related to cell cycle, carbohydrate metabolic process, and signal transduction are corroborated as mediators of the CIGB-552 antitumor activity (Supplementary Table S2a).

Target deconvolution based on the subtractions of sticky and core proteome proteins might remove a real drug target \[[@B28]\]. Nevertheless, this strategy has been previously used to identify the targets of BCR-ABL kinase inhibitor INNO-406 in chronic myeloid leukemia \[[@B30]\]. To overcome the potential disadvantage of removing real targets, a computational strategy was applied for identifying the functional subnetworks perturbed by CIGB-552. Such computational approach, named drugDisruptNet, was presented by Burkard et al. to predict the mechanism and potential side effects of drugs \[[@B14]\]. A functional subnetwork is defined as a connected fraction of the interactome in which all the proteins share the same function \[[@B14]\]. A drug can impact functional subnetworks directly (the drug target is part of the subnetwork) or indirectly (the drug target interacts with the protein subnetwork) \[[@B14]\]. Therefore, even if a CIGB-552 target is removed during the target deconvolution, the remaining potential targets might indicate the functional subnetworks perturbed by the drug.

To identify the functional subnetworks perturbed by CIGB-552, the filtered target profile (55 proteins) was used. As other studies have corroborated the role of COMMD1 in CIGB-552 cytotoxic effect \[[@B5]\], this protein was included in the network analysis. According to drugDisruptNet results ([Table 2](#tab2){ref-type="table"}), different subnetworks related to carcinogenesis were perturbed by CIGB-552, "antiapoptosis" and "negative regulation of cell cycle" among them. These results corroborate the antitumor effect of CIGB-552.

Additionally, "extracellular structure organization" and "response to hypoxia" were modulated by the CIGB-552 target profile ([Table 2](#tab2){ref-type="table"}). Both the composition and organization of the extracellular matrix and hypoxia are microenvironment signals that contribute to metastatic spread of cancer cells \[[@B31]\]. Therefore, CIGB-552 could inhibit metastasis in treated cells.

The "positive regulation of NF-*κ*B transcription factor activity" is disrupted by CIGB-552 ([Table 2](#tab2){ref-type="table"}). Although the target profile is not annotated in this signaling pathway, it acts at the periphery of the functional subnetwork ([Figure 4](#fig4){ref-type="fig"}). Previous results demonstrated that CIGB-552 treatment upregulates COMMD1 levels \[[@B5]\]. Such event increases RelA ubiquitination and consequently inhibits the NF-*κ*B signaling pathway \[[@B5]\]. In the present study, COMMD1 was not identified in the target profile. However, the "positive regulation of NF-*κ*B transcription factor activity" is disrupted by the CIGB-552 target profile essentially at two network nodes: RELA and TRAF6 ([Figure 4](#fig4){ref-type="fig"}).

NF-*κ*B transcription factor is a homo- or heterodimeric complex composed of REL proteins (RelA/p65, RelB, c-Rel, p50/p105, and p52/p100). RelA/p50 appears to be the most common heterodimer. After activation of I-kappa-B kinase complex (IKK), the active NF-*κ*B complex is translocated into the nucleus to regulate gene transcription \[[@B32]\]. NF-*κ*B target genes promote tumor cell proliferation, inhibition of apoptosis, migration, inflammation, and angiogenesis \[[@B33]\]. Therefore, upregulated NF-*κ*B activity has been reported in different tumor types including laryngeal and pancreatic cancers \[[@B34]--[@B36]\].

The TNF receptor-associated factor 6 (TRAF6) activates NF-*κ*B \[[@B37]\]. This mechanism depends on TRAF6-mediated TGF-beta-activated kinase 1 (MAP3K7/TAK1) activation, which in turn phosphorylates and activates the I-kappa-B kinase complex (IKK) \[[@B38]\]. MAP3K7/TAK1 also phosphorylates the dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6), which in turn activates the p38 MAPK signaling pathway \[[@B37]\]. In the present study, MAP2K6 and MAPK14 (mitogen-activated protein kinase 14) were identified as potential CIGB-552 targets ([Figure 4](#fig4){ref-type="fig"}). MAPK14 is a member of the p38 MAPK family. The p38 MAPKs phosphorylate different substrates, including the nuclear mitogen- and stress-activated protein kinase 1 (RPS6KA5/MSK1). MSK1 phosphorylates RelA and increases the transcriptional activity of NF-*κ*B \[[@B39]\]. Therefore, CIGB-552 could inhibit the NF-*κ*B signaling pathway in tumor cells by blocking the MAP2K6/MAPK14 functions.

Furthermore, persulfide dioxygenase ETHE1 (ETHE1) and lysine N-methyltransferase 7 (SETD7) were identified as potential CIGB-552 targets ([Figure 4](#fig4){ref-type="fig"}). Other studies demonstrate that both proteins regulate RelA transcriptional activity. ETHE1 protein promotes accumulation of RelA in the cytoplasm and consequently inhibits the NF-*κ*B transcriptional activity \[[@B40]\]. SETD7 protein monomethylates RelA subunit; this event triggers RelA degradation and downregulates NF-*κ*B target gene expression \[[@B41], [@B42]\]. The identification of ETHE1 and SETD7 in the target profile suggests that CIGB-552 could exert, by interacting with these proteins, different mechanisms to regulate RelA function.

Interleukin-6 (IL-6) expression is activated by NF-*κ*B transcription factor \[[@B43], [@B44]\]. The "interleukin-6 production" subnetwork was perturbed by CIGB-552 target profile ([Table 2](#tab2){ref-type="table"}). Therefore, disruption of this subnetwork could be a consequence of inhibiting NF-*κ*B transcriptional activity. Importantly, IL-6 downregulation could be validated as a subrogate marker of CIGB-552 antitumor effect.

CIGB-552 target interactions trigger cellular signaling events that finally accomplish the antitumor response. To investigate these signaling events at the protein level, an expression-based proteomics study was conducted. The majority of proteins identified by chemical proteomics as potential CIGB-552 targets (109/161) are located in the cytosol. Cytoplasmic proteins are also enriched after target deconvolution (36/55) (Supplementary Table S2b-c). Therefore, the cytoplasmic proteome regulated in the presence of 150 *μ*mol/L of CIGB-552 was studied using the HT-29 cell line as target cells. Such peptide dose represents the inhibitory concentration 80 (IC80) for CIGB-552 in HT-29 cells (unpublished results). Confocal microscopy demonstrates that after 10 min of incubation CIGB-552 is able to penetrate the cells \[[@B4]\]. In the present work, the proteomic profile modulated by CIGB-552 was investigated at three incubation times: 40 min, 2 h, and 5 h.

In both proteomic experiments, different tumor cell lines were used to evaluate consistence among results. HT-29 cells, as well as Hep-2 cells, have shown to be sensitive to CIGB-552 anticancer effect \[[@B4]\]. In addition, CIGB-552 was able to elicit significant antitumor activity in both murine CT-26 (colon carcinoma cells) and human HT-29 implanted tumors \[[@B6]\]. Consequently, the differentially expressed proteins in treated HT-29 cells could support the findings of the CIGB-552 target profile identified in total cell extracts from Hep-2 cells.

As a result, 658 protein hits were identified (Supplementary Table S3), of which 72 proteins were differentially modulated in at least one experimental condition (CIGB-552: 40 min, 2 h, and 5 h) with respect to control ([Table 3](#tab3){ref-type="table"}). A total of 68 proteins of the proteomic profile (658 protein hits), including eight differentially modulated proteins in response to CIGB-552 treatment, were also identified by chemical proteomics as potential CIGB-552 targets (Supplementary Table S3).

Bioinformatics analysis of comparative proteomic data demonstrated the enrichment of biological processes such as gene expression, proteolysis, and response to drug ([Figure 5](#fig5){ref-type="fig"}). Importantly, carbohydrate and nitrogen metabolic processes, protein transport, cell cycle, and regulation of apoptosis were found to be significantly represented in chemical and comparative proteomic profiles (Figures [2](#fig2){ref-type="fig"} and [5](#fig5){ref-type="fig"}). These results demonstrated that even in different cell lines (HT-29, Hep-2) the CIGB-552 antitumor effect is exerted by modulating similar biological processes.

Differentially expressed proteins related to apoptosis and cell cycle regulation support the CIGB-552 antitumor effect. Among them, the DNA replication licensing factor MCM6 (MCM6), the cyclin-G-associated kinase (GAK), and the S-phase kinase-associated protein 1 (SKP1), which function as positive regulators of cell cycle \[[@B25], [@B45], [@B46]\], were significantly downregulated after 40 min of CIGB-552 treatment.

As expected, on CIGB-552-treated cells, the apoptosis was a much later event than the negative regulation of cell cycle ([Figure 6](#fig6){ref-type="fig"}). Only after 2 h, the CIGB-552 treatment increased the expression of proapoptotic proteins. For instance, the voltage-dependent anion-selective channel protein 2 (VDAC2) was significantly upregulated after 2 h of CIGB-552 treatment. This protein is a component of the mitochondrial permeability transition pore complex, which releases apoptogenic factors, such as cytochrome C, during apoptosis \[[@B47], [@B48]\]. In line with this evidence, the expression of the cytochrome C-releasing factor 21 (GGCT) was increased sequentially on CIGB-552-treated cells, the upregulation being significant after 5 h of treatment. Furthermore, the expression of Bcl-2-associated transcription factor 1 (BCLAF1), a transcriptional repressor that promotes apoptosis \[[@B49], [@B50]\], was increased after 2 h of treatment with CIGB-552. Concomitant with upregulation of proapoptotic proteins, the expression of the major vault protein (MVP) was significantly decreased on HT-29 cells after 5 h of CIGB-552 treatment ([Figure 5](#fig5){ref-type="fig"}). MVP functions as a multidrug resistance factor \[[@B51]--[@B53]\]. Therefore, the downregulation of MVP could facilitate the proapoptotic effect in response to CIGB-552 treatment and overcome the chemotherapeutic resistance usually developed by cancer cells.

Most of the proteins related to proteolysis were downregulated by CIGB-552 treatment ([Figure 5](#fig5){ref-type="fig"}). Two peptidase M16 family members, which have metalloendopeptidase activity, were identified: the mitochondrial-processing peptidase subunit beta (PMPCB) and nardilysin (NRD1). Particularly, NRD1 protein promotes cell growth and invasion of cancer cells \[[@B54], [@B55]\]. In the present work, Calpain-2 (CAPN2) and proprotein convertase subtilisin/kexin type 6 (PCSK6) were also identified. Both proteins are proteases related to tumor progression. CAPN2 upregulation increases the invasive potential of different tumor cells; such effect has been associated with secretion of matrix metalloproteinases (MMP-2 and MMP-9) \[[@B56]--[@B58]\]. Besides, in the tumor microenvironment, the inhibition of Calpain blocks angiogenesis \[[@B59]\]. PCSK6 substrates include precursors of cancer related proteins such as matrix metalloproteinases and the vascular endothelial growth factor (VEGF) \[[@B60]\]. Therefore, upregulation of PCSK6 increases the invasiveness of carcinoma cells \[[@B61]--[@B63]\]. Indeed inhibition of PCSK6 has been proposed as an anticancer therapeutic strategy \[[@B64], [@B65]\]. Altogether, the concomitant downregulation of NRD1, CAPN2, and PCSK6 suggests that CIGB-552 treatment could inhibit cancer cell invasion, exerting a potential antimetastatic effect. As previously mentioned, the antimetastatic effect of CIGB-552 is also supported by chemical proteomics results. To validate such hypothesis other studies have been conducted.

To analyze chemical proteomic data in combination with differentially expressed proteins, an interaction network was represented ([Figure 7](#fig7){ref-type="fig"}). According to interaction databases, 18 differentially modulated proteins interact with the potential CIGB-552 target profile (18 proteins). Prohibitin (PHB) interacts with three proteins included in the CIGB-552 target profile (ACTN1, SET, and C1QBP) ([Figure 7](#fig7){ref-type="fig"}). The expression of PHB, which is a negative regulator of cell proliferation \[[@B66]\], was increased on CIGB-552-treated cells. Besides, prefoldin subunit 3 (PFDN3), upregulated by CIGB-552 treatment, interacts with the acidic leucine-rich nuclear phosphoprotein 32 family member A (ANP32A) ([Figure 7](#fig7){ref-type="fig"}). It is a tumor suppressor protein \[[@B67]\] that was identified as a potential CIGB-552 target. Additionally, PFDN3 binds to von Hippel-Lindau protein (VHL), which regulates ubiquitination and proteasomal degradation of the hypoxia-inducible factor 1-alpha (HIF-*α*) \[[@B68]\]. Functional subnetworks of "negative regulation of cell cycle" and "response to hypoxia" were perturbed by CIGB-552 target profile ([Table 2](#tab2){ref-type="table"}). Accordingly, such effects are supported by the upregulation of PHB and PFDN3 on HT-29 cells treated with CIGB-552.

The intersection between chemical proteomic data and differentially expressed proteins indicates potential mediators of CIGB-552 antitumor effect. The Rho GTPase-activating protein 1 (ARHGAP1) was identified as a potential CIGB-552 target ([Figure 7](#fig7){ref-type="fig"}). This protein inactivates signal transduction mediated by Rho-family GTPases, such as RhoA, Rac1, and CDC42 \[[@B69], [@B70]\]. Accordingly, the functional category of "small GTPase mediated signal transduction" was significantly represented in the proteomic profile modulated by CIGB-552 on HT-29 cells ([Figure 5](#fig5){ref-type="fig"}). In addition, ARHGAP1 interacts with Tax1-binding protein 1 (TAX1BP1) ([Figure 7](#fig7){ref-type="fig"}) \[[@B71]\]. The expression of TAX1BP1 was increased at 2 h of CIGB-552 treatment ([Table 3](#tab3){ref-type="table"}). TAX1BP1, in conjugation with the zinc finger protein A20, the E3 ubiquitin-protein ligase Itch, and RING finger protein 11, constitutes the A20 ubiquitin-editing protein complex \[[@B72]\]. Downstream to Toll-like receptor 4 (TLR4) and tumor necrosis factor receptor 1 (TNFR1) the A20 complex inactivates TRAF6 and RIP1, repressing the NF-*κ*B signaling pathway \[[@B73], [@B74]\]. Furthermore, in the present work, several potential CIGB-552 targets interact with TRAF6 ([Figure 4](#fig4){ref-type="fig"}). Altogether, these results suggest that CIGB-552 could inhibit the TRAF6/NF-*κ*B axis.

Other proteins related to NF-*κ*B signaling pathway were also modulated on HT-29 cells by CIGB-552. The S-phase kinase-associated protein 1 (SKP1) was downregulated at 40 min and 2 h after CIGB-552 treatment ([Figure 7](#fig7){ref-type="fig"}). This protein is an essential component of the SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex, which mediates the ubiquitination of proteins involved in cell cycle progression, signal transduction, and transcription \[[@B75]\]. As part of SCF complex, the F-box/WD repeat-containing protein 1A (BTRC) ubiquitinates I*κ*B leading to its proteasomal degradation and consequently NF-*κ*B activation \[[@B76]\]. In the present work, the F-box protein BTRC was not identified. However, by decreasing the expression of SKP1, CIGB-552 could compromise the function of SCF complex. SKP1 is a proteasome interacting protein ([Figure 7](#fig7){ref-type="fig"}) \[[@B77]\]. The expression of two proteasome subunits (PSMA2, PSMA7) was decreased at 2 h of CIGB-552 treatment ([Figure 7](#fig7){ref-type="fig"}). Besides, several components of the proteasome complex, including the subunit PSMA2, were identified by chemical proteomics as potential CIGB-552 targets ([Figure 3](#fig3){ref-type="fig"}). Interestingly, modulation of SKP1 and proteasome subunits is concomitant with TAX1BP1 upregulation ([Figure 6](#fig6){ref-type="fig"}). These results suggest that CIGB-552 potentiates, at 2 h following treatment, the inhibition of NF-*κ*B signaling pathway. Such effect is also supported by chemical proteomic results, as the "positive regulation of NF-*κ*B transcription factor activity" is a functional subnetwork disrupted by the CIGB-552 target profile ([Figure 4](#fig4){ref-type="fig"}).

A potential mechanism of NF-*κ*B inhibition by CIGB-552 was proposed based on both chemical and comparative proteomic profiles ([Figure 8](#fig8){ref-type="fig"}). Previous results demonstrated that CIGB-552 interacts with COMMD1 triggering the RelA ubiquitination \[[@B5]\]. Other potential CIGB-552 interactors include the proteins ETHE1 and SETD7. ETHE1 and SETD7, as well as COMMD1, regulate the function of RelA \[[@B40]--[@B42]\]. Therefore, CIGB-552 by interacting with ETHE1 and SETD7 could repress the transcription of NF-*κ*B target genes ([Figure 8](#fig8){ref-type="fig"}). As the MAPK cascade increases the transcriptional activity of RelA \[[@B39]\], interaction between CIGB-552 and MAPKs proteins (MAP2K6, MAPK14) could also inhibit the NF-*κ*B signaling pathway ([Figure 8](#fig8){ref-type="fig"}). Finally, the upregulation of TAX1BP1 and the downregulation of SKP1 induced by CIGB-552 are of great relevance. From a mechanistic view, the modulation of both proteins by CIGB-552 supports the inhibition of NF-*κ*B signaling pathway ([Figure 8](#fig8){ref-type="fig"}).

4. Conclusions {#sec4}
==============

This study explored at the proteomic level the CIGB-552 antitumor mechanism of action. The CIGB-552 target profile was investigated in Hep-2 cells using a chemical proteomic approach. In total, 161 proteins were identified as potential CIGB-552 targets. This target profile was reduced to 55 proteins by a target deconvolution strategy. According to chemical proteomic results, CIGB-552 could be a multitarget drug. Downstream to drug-target interactions proteins that mediate cellular response to CIGB-552 treatment were identified by a comparative proteomic experiment including time series (40 min, 2 h, and 5 h). The proteomic profile modulated by CIGB-552 on HT-29 cells includes 72 differentially expressed proteins. The results of both experimental approaches, chemical and expression-based proteomics, were highly consistent. Proteins related to NF-*κ*B signal transduction were identified as potential CIGB-552 targets and were significantly modulated by CIGB-552 treatment. Such findings are in line with previous results demonstrating that CIGB-552 blocks NF-*κ*B signaling by upregulation of COMMD1 and consequently ubiquitination of RelA. The proteomic data revealed new mediators for NF-*κ*B inhibition in response to CIGB-552 treatment. Proteins related to cell proliferation and apoptosis were identified by chemical and expression-based proteomics. These differentially expressed proteins could represent subrogate biomarkers of the CIGB-552 effect on tumor cells. The negative regulation of cell cycle and promotion of apoptosis seem to be early and late events, respectively, triggered by treatment with CIGB-552. Proteins related to cell invasion were differentially modulated on CIGB-552-treated cells. This biological process was also represented in the functional subnetworks perturbed by the potential CIGB-552 targets. Therefore, an antimetastatic effect could be expected as a consequence of CIGB-552 treatment. Further experiments are required to corroborate the role of identified proteins on mediating the anticancer effect of CIGB-552. Overall, the current study contributes to a better understanding of the CIGB-552 potentialities for cancer therapy.
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###### 

Supplementary Table S1a contains the proteins purified on the CIGB-552 streptavidin sepharose matrix from the Hep-2 cell lysate.

Supplementary Table S1b contains the CRAPome information about the central proteome proteins which were identified as part of the CIGB-552 target profile.

Supplementary Table S2a contains biological processes enriched in the CIGB-552 target profile after target deconvolution.

Supplementary Table S2b contains cellular components enriched in the CIGB-552 target profile.

Supplementary Table S2c contains cellular components enriched in the CIGB-552 target profile after target deconvolution.

Supplementary Table S3 contains the proteomic profile modulated by CIGB-552 in HT-29 cells.
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![Chemical proteomic approach (a) and results (b). (a) The streptavidin-sepharose (grey) biotinylated CIGB-552 complex retains the drug targets (green) and secondary binders (orange). Nonspecific proteins (blue) stick to the matrix. The retained proteins were eluted, separated by SDS-PAGE, and identified by LC-MS/MS. (b) Proteins eluted from the streptavidin-sepharose matrix were separated by SDS-PAGE. Molecular weight markers (MWM) displayed on the left. Lane I: protein cell extract (Hep-2 cell line); lane II: proteins eluted from the unloaded matrix (without CIGB-552-B); lane III: proteins eluted from the matrix bound to CIGB-552-B.](BMRI2015-124082.001){#fig1}

![Biological processes significantly represented in the CIGB-552 target profile (161 proteins). Proteins were classified according to annotations of Gene Ontology database; the enrichment analysis was performed using the GeneCodis bioinformatic tool.](BMRI2015-124082.002){#fig2}

![Protein complexes included in the CIGB-552 target profile (161 proteins). Biological processes related to protein complexes are illustrated. The analysis was conducted using CORUM database.](BMRI2015-124082.003){#fig3}

![CIGB-552 targets (green nodes) perturb the positive regulation of NF-*κ*B transcription factor activity. In the protein-protein interaction network, the CIGB-552 target profile (green nodes) interferes with proteins that share the same Gene Ontology term (triangular nodes). The node size is proportional to drug affinity, which was calculated based on the abundance of pulled-down proteins according to emPAI values. COMMD1 protein, which is a validated CIGB-552 target, is represented in the functional subnetwork with the maximal node size to illustrate a high drug affinity.](BMRI2015-124082.004){#fig4}

![Functional association network that illustrates the biological processes significantly represented (*p* values \< 0.05) in the proteomic profile modulated by CIGB-552 on HT-29 cells. Proteins were classified according to annotations of Gene Ontology database; the enrichment analysis was performed using the GeneCodis bioinformatic tool. The color of network nodes representing proteins is proportional to the fold change on CIGB-552-treated cells with respect to control.](BMRI2015-124082.005){#fig5}

![Identification of protein clusters related to cell cycle, apoptosis, and NF-*κ*B signaling, which showed similar trends of differential expression over time.](BMRI2015-124082.006){#fig6}

![Protein-protein interaction network that represents the intersection between the chemical (triangle nodes) and the comparative (circular nodes) proteomics profiles. The network was represented using BisoGenet plugin, which retrieves interaction data from multiple databases. For network nodes representing differentially expressed proteins, the color is proportional to the fold change on CIGB-552-treated cells with respect to control.](BMRI2015-124082.007){#fig7}

![Proposed mechanism for NF-*κ*B signaling inhibition mediated by the antitumor peptide CIGB-552. Different proteins, which regulate NF-*κ*B pathway, were differentially modulated by CIGB-552 treatment (TAX1BP1, SKP1, PSMA2/A2, and PSMA7/A7). In addition, the CIGB-552 target profile includes proteins that regulate RelA function (ETHE1, SETD7, and MAPK signaling: MAP2K6, MAPK14). Such interactions ultimately could repress the transcription of NF-*κ*B target genes. Altogether, by modulating the function of these proteins CIGB-552 could inhibit cell proliferation and induces apoptosis of tumor cells.](BMRI2015-124082.008){#fig8}

###### 

Proteins identified by chemical proteomics as potential CIGB-552 targets.

  UniProt ACC^a^   Description                                                                         Gene symbol^b^   Score^c^   emPAI^d^
  ---------------- ----------------------------------------------------------------------------------- ---------------- ---------- ----------
  O95218           Zinc finger Ran-binding domain-containing protein 2                                 ZRANB2           39         0.21
  Q9NX65           Zinc finger and SCAN domain-containing protein 32                                   ZSCAN32          26         0.05
  Q9UBQ0           Vacuolar protein sorting-associated protein 29                                      VPS29            56         0.66
  Q14376           UDP-glucose 4-epimerase                                                             GALE             38         0.1
  Q12888           Tumor suppressor p53-binding protein 1                                              TP53BP1          28         0.02
  O14773           Tripeptidyl-peptidase 1                                                             TPP1             76         0.06
  Q13428           Treacle protein                                                                     TCOF1            27         0.02
  P04183           Thymidine kinase, cytosolic                                                         TK1              24         0.15
  Q9NXG2           THUMP domain-containing protein 1                                                   THUMPD1          58         0.09
  Q8WW59           SPRY domain-containing protein 4                                                    SPRYD4           39         0.16
  P63151           Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform   PPP2R2A          87         0.07
  Q9NVA2           Septin-11                                                                           SEPT11           29         0.08
  O00764           Pyridoxal kinase                                                                    PDXK             59         0.11
  Q16740           ATP-dependent Clp protease proteolytic subunit, mitochondrial                       CLPP             67         0.26
  Q9Y4X5           E3 ubiquitin-protein ligase ARIH1                                                   ARIH1            29         0.06
  O15460           Prolyl 4-hydroxylase subunit alpha-2                                                P4HA2            41         0.12
  P40261           Nicotinamide N-methyltransferase                                                    NNMT             46         0.27
  P19105           Myosin regulatory light chain 12A                                                   MYL12A           200        2.45
  Q16539           Mitogen-activated protein kinase 14                                                 MAPK14           82         0.19
  Q9UNF1           Melanoma-associated antigen D2                                                      MAGED2           238        0.18
  P50213           Isocitrate dehydrogenase \[NAD\] subunit alpha, mitochondrial                       IDH3A            64         0.2
  P05161           Ubiquitin-like protein ISG15                                                        ISG15            34         0.21
  O00629           Importin subunit alpha-3                                                            KPNA4            49         0.06
  Q8WTS6           Histone-lysine N-methyltransferase SETD7                                            SETD7            42         0.09
  P06737           Glycogen phosphorylase, liver form                                                  PYGL             40         0.04
  P30712           Glutathione S-transferase theta-2                                                   GSTT2            96         0.14
  P47755           F-actin-capping protein subunit alpha-2                                             CAPZA2           109        0.38
  P52907           F-actin-capping protein subunit alpha-1                                             CAPZA1           118        0.54
  P41091           Eukaryotic translation initiation factor 2 subunit 3                                EIF2S3           43         0.07
  O95571           Persulfide dioxygenase ETHE1, mitochondrial                                         ETHE1            35         0.13
  Q9BVJ7           Dual specificity protein phosphatase 23                                             DUSP23           50         0.23
  P52564           Dual specificity mitogen-activated protein kinase kinase 6                          MAP2K6           29         0.1
  Q14691           DNA replication complex GINS protein PSF1                                           GINS1            24         0.16
  Q3LXA3           Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing)        DAK              45         0.06
  P21291           Cysteine and glycine-rich protein 1                                                 CSRP1            47         0.39
  Q99627           COP9 signalosome complex subunit 8                                                  COPS8            69         0.35
  Q9UBW8           COP9 signalosome complex subunit 7a                                                 COPS7A           46         0.12
  P61201           COP9 signalosome complex subunit 2                                                  COPS2            136        0.23
  Q07021           Complement component 1 Q subcomponent-binding protein, mitochondrial                C1QBP            648        1.74
  Q9NT62           Ubiquitin-like-conjugating enzyme ATG3                                              ATG3             58         0.1
  Q9BZZ5           Apoptosis inhibitor 5                                                               API5             173        0.13
  P12814           Alpha-actinin-1                                                                     ACTN1            1345       1.76
  P11766           Alcohol dehydrogenase class 3                                                       ADH5             78         0.19
  P36404           ADP-ribosylation factor-like protein 2                                              ARL2             38         0.4
  P40616           ADP-ribosylation factor-like protein 1                                              ARL1             39         0.19
  P84077           ADP-ribosylation factor 1                                                           ARF1             99         0.66
  P00813           Adenosine deaminase                                                                 ADA              35         0.09
  Q9BTT0           Acidic leucine-rich nuclear phosphoprotein 32 family member E                       ANP32E           169        0.41
  P84098           60S ribosomal protein L19                                                           RPL19            38         0.16
  P61586           Transforming protein RhoA                                                           RHOA             32         0.17
  Q07960           Rho GTPase-activating protein 1                                                     ARHGAP1          63         0.07
  Q14657           EKC/KEOPS complex subunit LAGE3                                                     LAGE3            34         0.26
  Q96IU4           Alpha/beta hydrolase domain-containing protein 14B                                  ABHD14B          67         0.17
  P39687           Acidic leucine-rich nuclear phosphoprotein 32 family member A                       ANP32A           286        1.38
  O75607           Nucleoplasmin-3                                                                     NPM3             33         0.2

^a^UniProtKB/Swiss-Prot entry accession number (<http://www.uniprot.org/>).

^b^Recommended gene name (official gene symbol) as provided by UniProtKB/Swiss-Prot.

^c^MASCOT protein score.

^d^emPAI: exponentially modified Protein Abundance Index.

###### 

Functional subnetworks perturbed by CIGB-552.

  Perturbed functional subnetworks                               GO id.^a^    Nodes   Targets^b^   Score *S* ~net~ ^c^
  -------------------------------------------------------------- ------------ ------- ------------ ---------------------
  Insulin receptor signaling pathway                             GO:0008286   57      15           0.175
  Positive regulation of biosynthetic process                    GO:0009891   73      19           0.173
  Positive regulation of NF-*κ*B transcription factor activity   GO:0051092   40      14           0.165
  Protein autoprocessing                                         GO:0016540   67      14           0.165
  Extracellular structure organization                           GO:0043062   66      13           0.143
  Mitochondrion organization                                     GO:0007005   68      17           0.136
  Antiapoptosis                                                  GO:0006916   178     26           0.112
  Interleukin-6 production                                       GO:0032635   21      8            0.105
  Response to hypoxia                                            GO:0001666   68      14           0.103
  Negative regulation of cell cycle                              GO:0045786   37      8            0.076

^a^GO id.: Gene Ontology identifier.

^b^Number of proteins related to the functional subnetwork and identified as potential CIGB-552 targets.

^c^ *S* ~net~: score calculated by drugDisruptNet, predicting the impact of CIGB-552 over the functional subnetwork.

###### 

Differentially expressed proteins in HT-29 cells treated with CIGB-552.

  UniProt ACC^a^             Description                                                                              Gene symbol^b^   Score^c^   Fold change^d^              
  -------------------------- ---------------------------------------------------------------------------------------- ---------------- ---------- ---------------- ---------- -----------
  *Downregulated proteins*                                                                                                                                                    
  **Q14566**                 DNA replication licensing factor MCM6                                                    MCM6             76.01      **−4.2**         −1.1       −2
  Q14764                     Major vault protein                                                                      MVP              88.9       −1.2             −1.9       **−2.6**
  **P35579**                 Myosin-9                                                                                 MYH9             166.85     −1.7             **−2.9**   −1.6
  P61160                     Actin-related protein 2                                                                  ACTR2            60.97      **−2.6**         −1.4       −1.8
  Q02338                     D-beta-hydroxybutyrate dehydrogenase, mitochondrial                                      BDH1             71.17      −1.7             −1.4       **−2.6**
  P20290                     Transcription factor BTF3                                                                BTF3             62.09      1.2              **−2.9**   −1.5
  Q7L1Q6                     Basic leucine zipper and W2 domain-containing protein 1                                  BZW1             95.07      −1.3             **−3.8**   −2.3
  P17655                     Calpain-2 catalytic subunit                                                              CAPN2            101.09     −1.3             **−3.1**   −1.9
  A8K010                     Putative uncharacterized protein C6orf176                                                C6orf176         33.72      −1.1             **−3.3**   −1.6
  P53618                     Coatomer subunit beta                                                                    COPB1            64.4       **−2.9**         −1.5       −1.4
  O60888                     Protein CutA                                                                             CUTA             62.42      1.2              −2.2       **−2.9**
  O14976                     Cyclin-G-associated kinase                                                               GAK              47.67      **−3.4**         **−3.8**   **−2.9**
  O95395                     Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3   GCNT3            59.62      **−3.2**         −1.2       −1.6
  P52306                     Rap1 GTPase-GDP dissociation stimulator 1                                                RAP1GDS1         66.74      −1.2             **−3**     −1.1
  O15228                     Dihydroxyacetone phosphate acyltransferase                                               GNPAT            46.58      **−4.5**         **−3.1**   −1.9
  Q86Y56                     HEAT repeat-containing protein 2                                                         HEATR2           63.07      −1.5             **−5**     −1.4
  Q6YP21                     Kynurenine-oxoglutarate transaminase 3                                                   CCBL2            39.9       1.7              **OFF**    1.5
  P43243                     Matrin-3                                                                                 MATR3            269.16     1                −1.2       **−4.5**
  O75439                     Mitochondrial-processing peptidase subunit beta                                          PMPCB            99.73      **−2.9**         1.2        −1.1
  **O43847**                 Nardilysin                                                                               NRD1             41.16      −1.3             **−2.9**   1.6
  O15270                     Serine palmitoyltransferase 2                                                            SPTLC2           62.71      **−3.2**         −2         **−2.5**
  P29122                     Proprotein convertase subtilisin/kexin type 6                                            PCSK6            30.52      −1.3             −1.5       **−16.7**
  P00491                     Purine nucleoside phosphorylase                                                          PNP              91.96      −2               **−5.6**   1.7
  **P25787**                 Proteasome subunit alpha type 2                                                          PSMA2            75.42      1.6              **−2.9**   1
  O14818                     Proteasome subunit alpha type 7                                                          PSMA7            103.36     −1.3             **−2.8**   −1.1
  Q13813                     Spectrin alpha chain, nonerythrocytic 1                                                  SPTAN1           112.76     −1.6             **−3.1**   −1.6
  Q9UL25                     Ras-related protein Rab-21                                                               RAB21            129.33     **−2.6**         1.1        −1.1
  Q9NV58                     E3 ubiquitin-protein ligase RNF19A                                                       RNF19A           31.17      −1.4             −1.8       **−4.8**
  P62081                     40S ribosomal protein S7                                                                 RPS7             65.3       **−4.2**         **−3.8**   **−2.6**
  Q96FQ6                     Protein S100-A16                                                                         S100A16          78         **−2.6**         −1.4       1
  P63208                     S-phase kinase-associated protein 1                                                      SKP1             72.23      **−7.1**         **−3.1**   1.2
  O00193                     Small acidic protein                                                                     SMAP             74.25      −1.5             **−2.6**   −1.3
  Q96JX3                     Protein SERAC1                                                                           SERAC1           32.13      −1.1             1.3        **−2.5**
  Q9Y5M8                     Signal recognition particle receptor subunit beta                                        SRPRB            54.95      −1.7             −1.1       **−2.9**
  Q96I99                     Succinyl-CoA ligase \[GDP-forming\] subunit beta, mitochondrial                          SUCLG2           85.7       −1.5             −2.4       **−2.4**
                                                                                                                                                                              
  *Upregulated proteins*                                                                                                                                                      
  O75223                     Gamma-glutamylcyclotransferase                                                           GGCT             37.33      1.1              2          **3.8**
  P61758                     Prefoldin subunit 3                                                                      VBP1             152.64     2.1              2.2        **2.5**
  Q9BWD1                     Acetyl-CoA acetyltransferase, cytosolic                                                  ACAT2            69.2       2.5              2          **3.2**
  Q86TX2                     Acyl-coenzyme A thioesterase 1                                                           ACOT1            73.32      **2.8**          1.6        **2.4**
  P02647                     Apolipoprotein A-I                                                                       APOA1            76.16      1.9              **2.7**    −1.1
  O00192                     Armadillo repeat protein deleted in velocardiofacial syndrome                            ARVCF            46         **ON**           **ON**     **ON**
  Q9NYF8                     Bcl-2-associated transcription factor 1                                                  BCLAF1           86.18      1                **ON**     **ON**
  O14523                     C2 domain-containing protein 2-like                                                      C2CD2L           31.3       **2.9**          1.7        2
  P60953                     Cell division control protein 42 homolog                                                 CDC42            52.58      2.3              1.5        **3.1**
  Q9UJS0                     Calcium-binding mitochondrial carrier protein Aralar2                                    SLC25A13         57.95      2.4              **3.4**    1.9
  O43809                     Cleavage and polyadenylation specificity factor subunit 5                                NUDT21           70.35      1.2              −1.7       **2.5**
  **Q96C86**                 Scavenger mRNA-decapping enzyme DcpS                                                     DCPS             70.59      1.5              2.1        **2.4**
  Q5TDH0                     Protein DDI1 homolog 2                                                                   DDI2             31.55      1                **ON**     **ON**
  P18858                     DNA ligase 1                                                                             LIG1             49.53      2.3              2.2        **2.6**
  Q5JZY3                     Ephrin type A receptor 10                                                                EPHA10           37.22      **ON**           **ON**     **ON**
  O76003                     Glutaredoxin-3                                                                           GLRX3            50.31      **3.2**          1.8        **2.4**
  Q14103                     Heterogeneous nuclear ribonucleoprotein D0                                               HNRNPD           138.39     1.4              **3**      1.4
  **Q96P70**                 Importin-9                                                                               IPO9             88.04      **3.9**          **2.9**    **2.9**
  **P33176**                 Kinesin-1 heavy chain                                                                    KIF5B            102.25     **4.3**          **3.6**    **5.1**
  P49006                     MARCKS-related protein                                                                   MARCKSL1         112.06     **ON**           **ON**     1
  Q9H3R2                     Mucin-13                                                                                 MUC13            68.36      1.8              **4.2**    1.9
  Q7Z406                     Myosin-14                                                                                MYH14            90.59      −1.1             **9.7**    −1.9
  Q9NX40                     OCIA domain-containing protein 1                                                         OCIAD1           87.8       **2.6**          **2.9**    2.3
  Q15102                     Platelet-activating factor acetylhydrolase IB subunit gamma                              PAFAH1B3         84.5       2.4              **62.4**   1.6
  O43252                     Bifunctional 3′-phosphoadenosine 5′-phosphosulfate synthetase 1                          PAPSS1           51.9       1                1          **ON**
  P36871                     Phosphoglucomutase-1                                                                     PGM1             105.24     **3.3**          −2.2       2.2
  P35232                     Prohibitin                                                                               PHB              90.52      **8.4**          **4.7**    **3.2**
  Q9UHJ6                     Sedoheptulokinase                                                                        SHPK             59.09      1                1          **ON**
  P52788                     Spermine synthase                                                                        SMS              60.56      −1.2             2.1        **3.2**
  Q01082                     Spectrin beta chain, brain 1                                                             SPTBN1           63.84      **ON**           **ON**     **ON**
  Q9Y3F4                     Serine-threonine kinase receptor-associated protein                                      STRAP            80.3       **2.9**          **3.7**    **4.5**
  **P26640**                 Valyl-tRNA synthetase                                                                    VARS             54.77      1.7              **3**      **3.5**
  Q86VP1                     Tax1-binding protein 1                                                                   TAX1BP1          31.29      2.3              **11.7**   1.2
  Q9HD45                     Transmembrane 9 superfamily member 3                                                     TM9SF3           71.54      1.5              **3.1**    −1.8
  P55327                     Tumor protein D52                                                                        TPD52            64.69      **5.9**          1.8        1.8
  P38606                     V-type proton ATPase catalytic subunit A                                                 ATP6V1A          66.31      −1.2             **4.4**    **2.8**
  P45880                     Voltage-dependent anion-selective channel protein 2                                      VDAC2            59.14      2.1              **4**      2

^a^UniProtKB/Swiss-Prot entry accession number (<http://www.uniprot.org/>). The UniProt accession numbers highlighted in bold indicate those proteins (8) that were also identified by chemical proteomics.

^b^Recommended gene name (official gene symbol) as provided by UniProtKB/Swiss-Prot.

^c^MASCOT protein score.

^d^Fold change of differentially regulated proteins after 40 min, 2 h, and 5 h of treatment with CIGB-552 \[(−) downregulated\]. For each incubation time with CIGB-552, is given the fold change threshold to consider a protein significantly up- or downregulated. The fold changes that have an absolute value higher than the threshold are highlighted in boldface.

[^1]: Academic Editor: Zheng Li
